Clinical Trial Results

Deltex Medical Group PLC
31 August 2006



                            Deltex Medical Group plc

              Major new trial shows CardioQTM reducing duration of
                          hospital stays by one third

31 August 2006 Deltex Medical Group plc ('Deltex Medical' or the 'Company'), the
UK's leading haemodynamic monitoring company, announces the publication today,
in the British Journal of Surgery, of the results of a major new clinical trial
using its CardioQ oesophageal Doppler monitors.

The study conducted at the Freeman Hospital in Newcastle demonstrated that in
cases where doctors used Deltex Medical's CardioQ treatment during surgery to
help better maintain fluid balance and blood circulation, those patients
suffered fewer complications and were fit for discharge three days sooner than
those who did not receive the treatment.

Specifically, the study's main findings showed that patients using CardioQ:

   •Were fit for discharge three days sooner (6 days versus 9 days);
   •Were actually discharged from hospital two days sooner (7 days versus 9
    days);
   •Suffered significantly fewer post-operative complications (2% of patients
    versus 15%);
   •Did not require unplanned intensive care (0% versus 11% of patients in
    the control group); and
   •Tolerated food significantly earlier (2 days versus 4 days after
    surgery).

The double-blinded prospective randomised controlled trial followed 108 patients
undergoing bowel surgery. Patients being treated under the guidance of the
CardioQ monitor were, on average, fit for discharge after six days and actually
discharged after seven days. Patients where the CardioQ was not used were, on
average, fit for discharge after nine days, three days longer. They were
actually discharged after nine days, two days longer.

Comparison between today's study and recent NHS data on outcome following major
bowel surgery shows that the average length of stay for patients treated at the
Freeman Hospital using the CardioQ is almost half that of the NHS average; 7
days compared with 15 days. A day in an NHS general or surgical ward costs up to
£400 a day, depending on additional care required; in an intensive care unit it
costs £1,200 or more according to the Department of Health published Healthcare
Resource Groups (HRGs) reference cost data. The potential productivity gains and
financial savings to the NHS from reducing the length of hospital stay are huge.

Use of the CardioQ has been proven to reduce length of hospital stay in numerous
different surgical specialities including orthopaedic, colorectal, cardiac and
general surgery. In evidence submitted to the Health Select Committee on June
2006, the Improving Surgical Outcomes Group (ISOG) estimated that up to one
million NHS patients a year could benefit from being treated under the guidance
of the CardioQ during surgery. If all NHS patients having major surgery were
treated with the CardioQ, the NHS could save between £350 million and £1 billion
a year, according to ISOG evidence.

Mr Alan Horgan, Consultant Colorectal Surgeon at the Freeman Hospital, leader of
the study said:

'These results are remarkable. Everyone involved in surgery and NHS management
should read this study.

'Fluid-balance during and after surgery is incredibly important to patient
wellbeing. Being able to monitor and maintain balance more accurately with
CardioQ has allowed us to take days off patient recovery time. We have proven
that it is possible to save the NHS both time and money, while also enhancing
patient care.'

Deltex Medical's chief executive, Andy Hill, commented:

'CardioQ has now been proven to work in seven independent randomised controlled
clinical trials. This study has shown once again that it benefits patients and
can deliver dramatic improvements to hospital productivity and financial
efficiency.

'In the current climate of financial deficits, embracing this technology should
be a no-brainer for the NHS. Fantastic results like this confirm once more that
NHS Trusts can both save money and improve patient care through prioritising the
adoption of our technology. We are working with large numbers of doctors
throughout the UK who are seeking the necessary funding to use the CardioQ as a
standard of care and we expect that this study will allow them to push harder
than ever before to secure that funding.'

For further information, please contact:-

Deltex Medical Group plc                        01243 774 837
Nigel Keen, Nigel Chairman                      [e-mail]
Andy Hill, Chief Executive                      [e-mail]
Ewan Phillips, Finance Director                 [e-mail]

Gavin Anderson & Company                        0207 554 1400
Deborah Walter                                  [e-mail]
Marie Cairney                                   [e-mail]
Jodie Reilly                                    [e-mail]

Charles Stanley Securities                      020 7149 6457
Philip Davies                                   [e-mail]


Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

   •Validated the results of the Monitor against known standards for
    measuring cardiac output, demonstrating that the technology works

   •Proved that the CardioQ works in a wide range of surgical procedures

   •Demonstrated that the Company's technology provides significant health
    and economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.




                      This information is provided by RNS
            The company news service from the London Stock Exchange